Factors affecting dose selection and outcome of cisapride treatment for dyspepsia in primary care

Alimentary Pharmacology and Therapeutics

Volumn 10, Issue 4, 1996, Pages 587-594

  Brunner, H ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b GENERAL HOSPITAL LINZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CISAPRIDE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG TOLERANCE; DYSPEPSIA; FATIGUE; FEMALE; HEADACHE; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHYSICIAN; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL;

EID: 0030055448     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1996.7149000.x     Document Type: Article

References (16)

1. Jones R, Lydeard S. Dyspepsia in the community: a follow-up study. Br J Clin Pract 1992; 46: 95-7.
2. Heading RC. Definitions of dyspepsia. Scand J Gastroenterol 1991; 26 (Suppl. 182): 1-6.
3. Nyren O. Therapeutic trial in dyspepsia: its role in the primary care setting. Scand J Gastroenterol 1991; 26(Suppl. 182): 61-69.
4. Heading RC. An appraisal of cisapride's efficacy in nonulcer dyspepsia. In: Heading RC, Wood JD, eds. Gastro-intestinal Dysmotility: Focus on Cisapride. New York: Raven Press, 1992: 227-35.
5. Coutant G, François I, De Nutte N, De Cock G, Rutgeerts L. Dose-response study of cisapride in the management of 'nonulcer-dyspepsia'. Prog Med 1987; 43(Suppl. 1): 91-6.
6. Hendrix R, Van Lint J. Experience with cisapride in the treatment of chronic functional dyspepsia. Prog Med 1987; 43(Suppl. 1): 6-75.
7. Heyse PM, Rambaldo R, Hazelhoff B. Factors affecting short-and long-term outcome of a short therapeutic trial with cisapride in dyspeptic patients. Scand J Gastroenterol 1993; 28(Suppl. 195): 15-24.
8. Verhaeghe J, Jaecques N, Rombouts J, et al. Functional dyspepsia versus other functional gastrointestinal disorders: a practical approach in Belgian general practice. Scand J Gastroenterol 1993; 28(Suppl. 195): 25-35.
9. Liehr H. A German drug-monitoring study in general practice patients receiving cisapride for functional dyspepsia. Scand J Gastroenterol 1993; 28(Suppl. 195): 54-9.
10. Fehr HF. Risk factors, co-medication, and concomitant diseases: their influence on the outcome of therapy with cisapride. Scand J Gastroenterol 1993; 28(Suppl. 195): 40-6.
11. Rösch W. Das neue Gastroprokinetikum Cisaprid (3 × 5 mg). Wie wirksam beim Reizmagen-Syndrom? Offene multizentrische Therapiestudie uber 2 bis 4 Wochen. Therapiewoche 1991; 41: 1868-72.
12. Fumagalli I, Hammer B. Cisapride versus metoclopramide in the treatment of functional dyspepsia - a double-blind comparative trial. Scand J Gastroenterol 1994; 29: 33-7.
13. Haug TT, Wilhelmsen I, Ursin H, Berstad A. What are the real problems for patients with functional dyspepsia? Scand J Gastroenterol 1995; 30: 97-100.
14. Wilhelmsen I, Haug TT, Ursin H, Berstad A. Discriminant analysis of factors distinguishing patients with functional dyspepsia from patients with duodenal ulcer. Significance of somatization. Dig Dis Sci 1995; 40: 1105-11.
15. Drossmann DA, Li X, Andruzzi E, et al. US householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993; 38: 1569-80.
16. Jones RH, Lydeard SE, Hobbs FDR, et al. Dyspepsia in England and Scotland. Gut 1990; 31: 401-5.